John Lee - Decibel Therapeutics Chief Officer
| DBTXDelisted Stock | USD 3.08 0.02 0.65% |
Insider
John Lee is Chief Officer of Decibel Therapeutics
| Age | 55 |
| Phone | 617 370 8701 |
| Web | https://www.decibeltx.com |
John Lee Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Lee against Decibel Therapeutics stock is an integral part of due diligence when investing in Decibel Therapeutics. John Lee insider activity provides valuable insight into whether Decibel Therapeutics is net buyers or sellers over its current business cycle. Note, Decibel Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Decibel Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Lee over six months ago Acquisition by John Lee of 14041 shares of MKS Instruments subject to Rule 16b-3 | ||
John Lee over a year ago Acquisition by John Lee of 120000 shares of Decibel Therapeutics subject to Rule 16b-3 |
Decibel Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3265) % which means that it has lost $0.3265 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7676) %, meaning that it created substantial loss on money invested by shareholders. Decibel Therapeutics' management efficiency ratios could be used to measure how well Decibel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Decibel Therapeutics currently holds 14.05 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Decibel Therapeutics has a current ratio of 6.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Decibel Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| Alfredo Castro | Ikena Oncology | N/A | |
| Robyn Sweinhart | Rezolute | N/A | |
| Chulani Karunatilake | Werewolf Therapeutics | 64 | |
| Daniel Hicklin | Werewolf Therapeutics | 60 | |
| Eric Lindquist | Celcuity LLC | N/A | |
| MBA MD | Ikena Oncology | 59 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Hunter MD | Aerovate Therapeutics | 58 | |
| MD FACP | AN2 Therapeutics | 76 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| Brian Sullivan | Celcuity LLC | 62 | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| , MBA | Molecular Partners AG | 51 | |
Management Performance
| Return On Equity | -0.77 | |||
| Return On Asset | -0.33 |
Decibel Therapeutics Leadership Team
Elected by the shareholders, the Decibel Therapeutics' board of directors comprises two types of representatives: Decibel Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Decibel. The board's role is to monitor Decibel Therapeutics' management team and ensure that shareholders' interests are well served. Decibel Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Decibel Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna MA, Ex Officer | ||
| Gabriel Corfas, CoFounder Board | ||
| James Murphy, Principal CFO | ||
| Charles Liberman, CoFounder Board | ||
| John Lee, Chief Officer | ||
| Joe Burns, VP Discovery | ||
| Elaine Cope, VP Operations | ||
| Ulrich Mller, CoFounder Board | ||
| Laurence Reid, CEO Pres | ||
| Albert Edge, CoFounder Board |
Decibel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Decibel Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.77 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 62.95 M | |||
| Shares Outstanding | 25.13 M | |||
| Shares Owned By Insiders | 13.35 % | |||
| Shares Owned By Institutions | 61.90 % | |||
| Number Of Shares Shorted | 78.33 K | |||
| Price To Book | 0.67 X | |||
| EBITDA | (62.49 M) | |||
| Net Income | (63.01 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Decibel Stock
If you are still planning to invest in Decibel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Decibel Therapeutics' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |